12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Baricitinib: Additional Phase IIb data

Data from 201 patients in the open-label extension of the double-blind, international Phase IIb JADA trial in 301 patients with active RA who were on stable doses of methotrexate showed that once-daily oral baricitinib maintained ACR20, ACR50 and ACR70 response rates from week 24 to week 52. Specifically, baricitinib produced ACR20 response rates at week 52 of 79% at the 4 mg dose and 66% at the 8 mg dose. ACR50 response rates at week 52 were 56% for the low dose and 50% for the high dose. ACR70 response rates at week 52 were 38% for the low dose and 28%...

Read the full 497 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >